Canada's PMPRB Tables 2025 Report on Patented Medicine Prices
3 reports, 1 independent
Updated Sat 03:30
No new developments lately
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The Patented Medicine Prices Review Board tabled its 2025 Annual Report, which reviews trends in the prices and sales of patented medicines in Canada. The report noted that sales of patented medicines reached $24.4 billion in 2025, representing 48% of all medicine sales in Canada. In 2025, 1,086 patented medicines for human use were reported to the board.
Why it matters
The PMPRB reviews patented medicine prices to protect Canadians from excessive pricing related to patents. The report highlighted that Canadian list prices were the third highest among the PMPRB11 countries and ranked seventh highest among 35 Organization for Economic Co-operation and Development countries.
Who's involved
- Patented Medicine Prices Review BoardOrganization responsible for reviewing patented medicine prices in Canada
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Senate receives PMPRB report on Canada's medicine pricesThe Senate receives the PMPRB's 2025 report on medicine prices and pharmaceutical trendsAlready happening
- How could the PMPRB's 2025 Annual Report affect the House of Commons' oversight role?PMPRB tables report detailing high Canadian medicine pricesAlready happening
Keep exploring
The entities involved
-
Patented Medicine Prices Review Board
organization
Nothing else this week.